Skip to main content

Table 1 Baseline clinical characteristics

From: Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

Patient-level characteristics Sirolimus- and probucol-eluting stent (n = 575) Zotarolimus-eluting stent (n = 295) P value
Age (years) 69 (61–76) 70 (62–76) 0.40
Female 150 (26.1) 79 (26.8) 0.83
Diabetes mellitus therapy
Insulin 197 (34.0) 109 (37.0) 0.43
Oral antidiabetic drugs 289 (50.0) 149 (51.0) 0.94
Hypertension 547 (95.1) 281 (95.3) 0.94
Hypercholesterolemia 389 (68.0) 188 (64.0) 0.25
Current smoker 105 (18.0) 52 (18.0) 0.82
Prior myocardial infarction 177 (30.8) 85 (28.8) 0.55
Prior bypass surgery 59 (10.3) 34 (11.5) 0.57
Clinical presentation 0.46
Silent ischemia 36 (6.3) 15 (5.1)  
Stable angina 324 (56.3) 154 (52.2)  
Unstable angina 98 (17.0) 61 (20.7)  
Non ST-segment elevation myocardial infarction 73 (12.7) 45 (15.3)  
ST-segment elevation myocardial infarction 44 (7.7 %) 20 (6.8 %)  
Multi-vessel disease 517 (89.9) 263 (89.2) 0.73
Ejection fraction (%)a 54 (44-60) 55 (41–61) 0.56
Lesion-level characteristics Sirolimus- and probucol-eluting stent (n = 849) Zotarolimus-eluting stent (n = 439) P value
Target vessel 0.11
Left anterior descending 336 (39.6) 196 (44.6)  
Left circumflex 236 (27.8) 123 (28.0)
Right coronary artery 277 (32.6) 120 (27.3)
Chronic total occlusion 56 (6.6) 22 (5.0) 0.26
Bifurcation 200 (23.6) 112 (25.5) 0.44
Ostial 152 (17.9) 80 (18.2) 0.89
Complex morphology 626 (74.0) 336 (77.0) 0.27
Lesion length (mm) 16.6 ± 9.5 17.9 ± 10.4 0.07
Reference vessel diameter (mm) 2.75 ± 0.52 2.79 ± 0.51 0.36
Minimal luminal diameter (mm) 0.91 ± 0.50 0.92 ± 0.47 0.83
Percent diameter stenosis (%) 67 ± 16 67 ± 15 0.83
  1. Data shown as mean ± SD, median (25th–75th percentiles), or n (%)
  2. aData available for 725 patients (86.7 %)